NJ data regs may not pose threat for HIOs

Share this article:
New Jersey's Division of Consumer Affairs recommended tight controls on data-mining, among other limits designed to prevent conflicts of interest in medicine. But health information organizations, it would seem, only have to worry about some of those proposed rules.

The data-mining proposals accompany the division's Report on Physician Compensation Arrangements, which also covers areas such as gifts, financial disclosure and CME.

Attorney General Anne Milgram issued an endorsement.

However, in order to restrict the use and sale of prescriber-identifiable information for commercial purposes, the report recommends legislation, and this has little chance of advancing with Chris Christie, a Republican, set to replace Democrat John Corzine as governor.

The AG and other cabinet members are expected to tender resignations on inauguration day. Christie is pro-business and pro-pharma. As his chief of staff, he appointed Richard Bagger, a Pfizer executive and former state legislator.

Other data-related provisions could be enacted by the state's Board of Medical Examiners after a six-month comment period, though.

One calls for notifying doctors, upon renewing their licenses, that they can use AMA's opt-out program to prevent having Rx information sold by pharmacists. The Board of Pharmacy is also urged to amend its rules to require pharmacies to document doctors' consent to the sale of data.


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?